Therapeutic Strategies in the Development of Anti-viral Drugs and
Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein - ScienceDirect
COVID-19 Vaccines - Region of Durham
Not available in Canada: A look at COVID-19 vaccine tech from
Immune Network
PDF) Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2
Azvudine (FNC): a promising clinical candidate for COVID-19 treatment
Chemokines and chemokine receptors during COVID-19 infection
News & Comment Cellular & Molecular Immunology
)
